News Releases Keyword search Year None20212020201920182017201620152014201320122011201020092008 3/25/2021 AcelRx Pharmaceuticals Announces Clinical Data Reporting High Ratings for Healthcare Professional and Patient Satisfaction Following Use of DSUVIA® for Acute Pain in Hospital Settings 3/22/2021 AcelRx Announces Presentation and Fireside Chat at the Benzinga Biotech Small Cap Conference 3/15/2021 AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results 3/8/2021 AcelRx to Host Fourth Quarter and Full Year 2020 Financial Results Call and Webcast on March 15, 2021 2/17/2021 AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Patients Undergoing Plastic Surgery Procedures 1/20/2021 AcelRx Announces Pricing of $27.5 Million Public Offering of Common Stock 1/19/2021 AcelRx Announces Underwritten Public Offering of Common Stock 1/19/2021 AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Cardiac Surgery Enhanced Recovery Regimen 1/14/2021 AcelRx Announces Year-End 2020 Metrics and Review of 2020 Achievements First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Print Page RSS Feeds
Keyword search Year None20212020201920182017201620152014201320122011201020092008 3/25/2021 AcelRx Pharmaceuticals Announces Clinical Data Reporting High Ratings for Healthcare Professional and Patient Satisfaction Following Use of DSUVIA® for Acute Pain in Hospital Settings 3/22/2021 AcelRx Announces Presentation and Fireside Chat at the Benzinga Biotech Small Cap Conference 3/15/2021 AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results 3/8/2021 AcelRx to Host Fourth Quarter and Full Year 2020 Financial Results Call and Webcast on March 15, 2021 2/17/2021 AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Patients Undergoing Plastic Surgery Procedures 1/20/2021 AcelRx Announces Pricing of $27.5 Million Public Offering of Common Stock 1/19/2021 AcelRx Announces Underwritten Public Offering of Common Stock 1/19/2021 AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Cardiac Surgery Enhanced Recovery Regimen 1/14/2021 AcelRx Announces Year-End 2020 Metrics and Review of 2020 Achievements First page « first Previous page ‹ previous Page 1 Page 2 Current page 3
3/25/2021 AcelRx Pharmaceuticals Announces Clinical Data Reporting High Ratings for Healthcare Professional and Patient Satisfaction Following Use of DSUVIA® for Acute Pain in Hospital Settings
3/22/2021 AcelRx Announces Presentation and Fireside Chat at the Benzinga Biotech Small Cap Conference
3/8/2021 AcelRx to Host Fourth Quarter and Full Year 2020 Financial Results Call and Webcast on March 15, 2021
2/17/2021 AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Patients Undergoing Plastic Surgery Procedures
1/19/2021 AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Cardiac Surgery Enhanced Recovery Regimen
